Skip to content

Reference Drug

DRUG17 trials

Sponsors

Pfizer, Chong Kun Dang Pharmaceutical, University of Karachi, AJU Pharm Co., Ltd., SANGMYUNG innovation

Conditions

BioequivalenceCardiovascular DiseasesDyslipidemiaEthinylestradiolGestodeneHarmonetHealthy IndividualsHypercholerolemia

Phase 1

A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
CompletedNCT01260805
PfizerBioequivalence, Ethinylestradiol, Gestodene +1
Start: 2010-09-30End: 2010-10-31Target: 32Updated: 2011-02-21
Diflucan Bioequivalence Study For Transferring The Manufacture
CompletedNCT03821480
PfizerBioequivalence
Start: 2019-01-28End: 2019-03-06Updated: 2021-07-16
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers
CompletedNCT04075643
Chong Kun Dang PharmaceuticalCardiovascular Diseases
Start: 2019-09-19End: 2019-10-30Updated: 2020-02-05
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
CompletedNCT04083872
Chong Kun Dang PharmaceuticalCardiovascular Diseases
Start: 2019-09-06End: 2019-11-01Updated: 2020-02-05
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
CompletedNCT04083846
Chong Kun Dang PharmaceuticalCardiovascular Diseases
Start: 2019-09-06End: 2019-10-25Updated: 2020-02-05
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389
NCT04322032
Chong Kun Dang PharmaceuticalType 2 Diabetes
Start: 2020-04-06End: 2020-05-18Target: 34Updated: 2020-03-26
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions
NCT04651881
Chong Kun Dang PharmaceuticalCardiovascular Diseases
Start: 2020-10-27End: 2020-12-09Updated: 2020-12-03
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions
NCT04678388
Chong Kun Dang PharmaceuticalCardiovascular Diseases
Start: 2020-10-29End: 2020-12-12Target: 24Updated: 2020-12-21
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults
CompletedNCT06931327
AJU Pharm Co., Ltd.Hypercholesterolemia
Start: 2025-03-29End: 2025-04-18Updated: 2025-06-12
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults
Active, not recruitingNCT06933459
AJU Pharm Co., Ltd.Dyslipidemia
Start: 2025-05-24End: 2025-06-24Updated: 2025-06-12
Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers
CompletedNCT07581028
AJU Pharm Co., Ltd.Dyslipidemia, Hypercholerolemia
Start: 2026-08-06End: 2026-08-28Updated: 2026-09-09
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions
RecruitingNCT07643220
AJU Pharm Co., Ltd.Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Start: 2026-06-01End: 2026-07-01Target: 44Updated: 2026-06-12
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions
Not yet recruitingNCT07643233
AJU Pharm Co., Ltd.Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Start: 2026-07-01End: 2026-08-01Target: 36Updated: 2026-06-11
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
CompletedNCT07655960
AJU Pharm Co., Ltd.Dyslipidemia, Hypercholesterolemia
Start: 2026-06-11End: 2026-07-03Updated: 2026-07-10

Phase 2

Phase 3

Unknown Phase